View Older Stories View More Recent Stories

Jun 20, 2016 05:14PM Form SC 13D/A RESPONSE BIOMEDICAL CORP Filed by: ORBIMED ADVISORS LLC
Jun 17, 2016 07:32PM Response Biomedical Corp. Announces Closing of First Tranche of Private Placement
Jun 17, 2016 01:35PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 16, 2016 06:00PM Form 4 Corvus Pharmaceuticals, For: Jun 14 Filed by: ORBIMED ADVISORS LLC
Jun 16, 2016 03:30AM Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement
Jun 13, 2016 05:18PM Form 4 Corvus Pharmaceuticals, For: Jun 09 Filed by: ORBIMED ADVISORS LLC
Jun 13, 2016 08:30AM Alpine Immune Sciences Announces $48 Million Series A Financing to Support Discovery and Development of the Next Generation of Immunotherapies
Jun 9, 2016 02:55PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 7, 2016 04:52PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Jun 3, 2016 05:23PM Form SC 13D/A Relypsa Inc Filed by: ORBIMED ADVISORS LLC
Jun 3, 2016 12:55PM Unusual 11 Mid-Day Movers 6/3: (LBIO) (EBIO) (JVA) Higher; (GSAT) (GOGO) (IMMU) Lower
Jun 3, 2016 09:36AM Lion Biotechnologies (LBIO) Names Maria Fardis, Ph.D., as CEO; Board Appointments Announced
Jun 3, 2016 09:34AM Lion Biotechnologies Appoints Maria Fardis, Ph.D., as CEO
Jun 3, 2016 09:00AM Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer
May 24, 2016 04:38PM Form 4 Corvus Pharmaceuticals, For: May 20 Filed by: ORBIMED ADVISORS LLC
May 20, 2016 05:22PM Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: ORBIMED ADVISORS LLC
May 20, 2016 04:07PM Form SC 13D Intellia Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 16, 2016 04:45PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 13, 2016 05:10PM Form 4 Intellia Therapeutics, For: May 11 Filed by: ORBIMED ADVISORS LLC
May 2, 2016 08:00AM Graybug Vision Announces $44.5 Million Series B Financing
Apr 27, 2016 08:00AM Critical Outcome Technologies Augments Advisory Board Drug Development Experience
Apr 19, 2016 05:54PM Xtent, Inc. (XTNT) Prelim. Q1 Rev. Misses Consensus
Apr 19, 2016 05:50PM Xtant Medical Pre-Announces First Quarter 2016 Revenue
Apr 19, 2016 05:02PM Form 3 Aeglea BioTherapeutics, For: Apr 12 Filed by: ORBIMED ADVISORS LLC
Apr 18, 2016 03:25PM Form SC 13G Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
Apr 13, 2016 10:21AM Form SC 13G/A Biotie Therapies Corp. Filed by: ORBIMED ADVISORS LLC
Apr 12, 2016 04:21PM Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act
Apr 1, 2016 01:11PM Form SC 13D Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Mar 31, 2016 04:45PM Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
Mar 29, 2016 12:21PM Form 4 Corvus Pharmaceuticals, For: Mar 29 Filed by: ORBIMED ADVISORS LLC
Mar 17, 2016 11:57AM Form SC 13D/A Affimed N.V. Filed by: ORBIMED ADVISORS LLC
Mar 16, 2016 03:30PM Form SC 13D/A Otonomy, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 16, 2016 07:45AM New Rational Combinations for Immuno-Oncology Conference Announced for NYC Addressing Novel Trial Designs and Business Development Strategies
Feb 16, 2016 04:31PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 16, 2016 03:48PM Form SC 13G/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 02:07PM Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:37PM Form SC 13G/A SYNERGY PHARMACEUTICALS, Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:34PM Form SC 13G IMMUNOMEDICS INC Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:31PM Form SC 13G eHealth, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:28PM Form SC 13G DYNAVAX TECHNOLOGIES Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:27PM Form SC 13G ProNAi Therapeutics Inc Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:23PM Form SC 13G/A COGENTIX MEDICAL INC Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 12:18PM Form SC 13G/A Biodel Inc Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 08:11AM Unilife Corp. (UNIS), Amgen (AMGN) Extend Exclusivity Period; Unilife Announces Amendment to Credit Agreement
Feb 16, 2016 06:24AM Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: ORBIMED ADVISORS LLC
Feb 16, 2016 06:20AM Form SC 13G/A Cynapsus Therapeutics Filed by: ORBIMED ADVISORS LLC
Feb 12, 2016 03:17PM Form SC 13G/A IMPAX LABORATORIES INC Filed by: ORBIMED ADVISORS LLC
Feb 12, 2016 03:15PM Form SC 13G Insys Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 12, 2016 03:12PM Form SC 13G INSMED Inc Filed by: ORBIMED ADVISORS LLC
Feb 12, 2016 03:09PM Form SC 13G/A INFINITY PHARMACEUTICALS Filed by: ORBIMED ADVISORS LLC
View More Recent Stories View Older Stories